Abbonarsi

Factors associated with rhythm control treatment decisions in patients with atrial fibrillation—Insights from the NCDR PINNACLE registry - 27/09/17

Doi : 10.1016/j.ahj.2017.02.006 
Anil K. Gehi, MD a, , Gheorghe Doros, PhD b, c, Thomas J. Glorioso, MS d, e, Gary K. Grunwald, PhD d, e, Jonathan Hsu, MD f, Yang Song, MS b, Mintu P. Turakhia, MD g, Alexander Turchin, MD, MS b, h, Salim S. Virani, MD, PhD i, Thomas M. Maddox, MD, MS e
a Section of Cardiac Electrophysiology, Division of Cardiology, University of North Carolina, Chapel Hill, NC 
b Harvard Clinical Research Institute, Boston, MA 
c Department of Biostatistics, Boston University, Boston, MA 
d Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 
e VA Eastern Colorado Health Care System, University of Colorado School of Medicine, and the Colorado Cardiovascular Outcomes Research Consortium, Denver, CO 
f Section of Cardiac Electrophysiology, Division of Cardiology, University of California San Diego, La Jolla, CA 
g VA Palo Alto Health Care System, Palo Alto, CA, and Department of Medicine Stanford University School of Medicine, Stanford, CA 
h Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA 
i Michael E. DeBakey VA Medical Center and Department of Medicine/Cardiology, Baylor College of Medicine 

Reprint requests: Anil K. Gehi, MD, CB 7075, 160 Dental Cir, University of North Carolina, Chapel Hill, NC 27599.CB 7075, 160 Dental Cir, University of North CarolinaChapel HillNC27599

Abstract

Background

Decisions to use rhythm control in atrial fibrillation (AF) should generally be dictated by patient factors, such as quality of life, heart failure, and other comorbidities. Whether or not other factors affect decisions about the use of rhythm control, and catheter ablation in particular, is unknown.

Methods

A cohort of all patients diagnosed with nonvalvular AF were identified from the National Cardiovascular Data Registry’s Practice Innovation and Clinical Excellence (PINNACLE) AF registry of US outpatient cardiology practices during the study period from May 1, 2008, to December 31, 2014. Overall and practice-specific rates of rhythm control (cardioversion, antiarrhythmic drug therapy, or catheter ablation) were assessed. We assessed patient and practice factors associated with rhythm control and determined the relative contribution of patient, practice, and unmeasured practice factors with its use.

Results

Among 511,958 PINNACLE AF patients, 22.3% were treated with rhythm control and 2.9% underwent catheter ablation. Significant practice variation in rhythm control was present (median rate of rhythm control across practices 22.8%, range 0.2%-62.9%). Significant patient factors associated with rhythm control therapy included white (vs nonwhite) race (odds ratio [OR] 2.43, P<.001), private (vs nonprivate) insurance (OR 1.04, P<.001), and whether a patient was seen by an electrophysiologist (OR 1.77, P<.001). In an analysis of the relative contribution of patient, practice, and unmeasured practice factors with rhythm control, the contribution of unmeasured practice factors (95% range OR 0.29-3.44) exceeded that of either patient (95% range OR 0.46-2.30) or practice (95% range OR 0.15-2.77) factors.

Conclusions

One in 5 AF patients in the PINNACLE registry received rhythm control, and 1 in 50 received catheter ablation, suggesting that rhythm control may be underused. A variety of measured and unmeasured practice factors unrelated to patient characteristics play a disproportionate role in the use of rhythm control treatment decisions. Understanding the drivers of these decisions may identify inappropriate treatment variation and better inform optimal use of these therapies.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Funding sources: This research was supported by the American College of Cardiology Foundation's National Cardiovascular Data Registry.


© 2017  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 187

P. 88-97 - Maggio 2017 Ritorno al numero
Articolo precedente Articolo precedente
  • Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines–Coronary Artery Disease (GWTG-CAD) program
  • Prakash Deedwania, Tushar Acharya, Kamal Kotak, Gregg C. Fonarow, Christopher P. Cannon, Warren K. Laskey, W. Frank Peacock, Wenqin Pan, Deepak L. Bhatt, GWTG Steering Committee and Investigators
| Articolo seguente Articolo seguente
  • Percutaneous revascularization in patients treated with thoracic radiation for cancer
  • Erin A. Fender, Jackson J. Liang, Terence T. Sio, John M. Stulak, Ryan J. Lennon, Joshua P. Slusser, Jonathan B. Ashman, Robert C. Miller, Joerg Herrmann, Abhiram Prasad, Gurpreet S. Sandhu

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.